TENAX THERAPEUTICS, INC. — Form 8-K
Filed July 2, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 72/100
What the filing says
Tenax Therapeutics announced its Phase 3 LEVEL clinical trial evaluating TNX-103 (oral levosimendag) for pulmonary hypertension in heart failure with preserved ejection fraction (PH-HFpEF) will present results in a late-breaking session at the European Society of Cardiology Congress on August 29, 2026 in Munich. The trial enrolled >230 patients (completed March 2026); a December 2025 blinded sample size re-estimation confirmed >90% power to detect a 25-meter change in 6-minute walk distance (primary endpoint). Company expects to report topline data in August 2026.
Why this rating
Pivotal Phase 3 trial readout imminent for pre-revenue $23.8M biotech; unmet need in PH-HFpEF; regulatory path visible. Material to company trajectory.
View original filing on SEC.gov ↗
See more from July 2, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.